CPHI China 2025 Concludes Successfully

The 23rd CPHI China 2025 wrapped up successfully in Shanghai on June 26. As a pivotal global barometer for the pharmaceutical ingredients industry, CPHI China serves as a critical platform for tracking industry trends, building collaborative networks, and evaluating innovative technologies.

AVT Pharmaceutical Excipients (Booth: E3E36) showcased once again at this year's event. Our specialized sales and technical support team engaged with over 1,000 global industry professionals, presenting key excipients for nucleic acid therapeutics, biologics, vaccine adjuvants, and medical aesthetics. In-depth discussions addressed specific R&D and manufacturing challenges.

AVT Pharmaceutical Excipients  showcased once again at this year's event. Our specialized sales and technical support team engaged with over 1,000 global industry professionals, presenting key excipients for nucleic acid therapeutics, biologics, vaccine adjuvants, and medical aesthetics. In-depth discussions addressed specific R&D and manufacturing challenges.

Leveraging extensive technical expertise and application support experience, the AVT team exchanged insights with R&D peers on product characteristics, application cases, and technical pain points. Significant interest was shown in our product lines—particularly nucleic acid delivery systems, biologics excipients, vaccine adjuvants, and medical aesthetics ingredients. While the exhibition has ended, collaboration and innovation continue.

AVT sincerely thanks our pharmaceutical R&D partners for their ongoing trust and engagement. Moving forward, we remain steadfastly committed to advancing high-end injectable excipients. We will continue providing comprehensive, specialized, and timely technical support alongside customized services to accelerate global drug developers’ journey from discovery to market.

We look forward to collaborating with R&D experts worldwide to drive innovation and breakthroughs in novel therapeutics!